tralokinumab (Adtralza) Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

cat-354 | tralokinumab

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Dermatitis, Atopic (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Alopecia Areata (Phase 2)

Asthma (Phase 3)

Colitis, Ulcerative (Phase 2)

Dermatitis, Atopic (Phase 3)

Diabetes Mellitus, Type 2 (Phase 1)

Healthy Volunteers (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 2)

Leiomyoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue